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Abstract
Background: Pneumococcal meningitis is associated with high risk of neurological sequelae such as cognitive
impairment and hearing loss. These sequelae are due to parenchymal brain and inner ear damage primarily induced
by the excessive inflammatory reaction in response to bacterial brain invasion. Metformin—a biguanide drug to treat
diabetes mellitus type 2—was recently found to suppress neuroinflammation and induce neuroregeneration. This
study evaluated the effect of metformin adjunctive to antibiotics on neuroinflammation, brain and inner ear damage,
and neurofunctional outcome in experimental pediatric pneumococcal meningitis.
Methods: Eleven-day-old Wistar rats were infected intracisternally with 5.22 ± 1.27 × 103 CFU Streptococcus pneumoniae
and randomized for treatment with metformin (50 mg/kg, i.p., once daily for 3 weeks) plus ceftriaxone (100 mg/kg, i.p.,
bid, n = 61) or ceftriaxone monotherapy (n = 79). Cortical damage and hippocampal apoptosis were evaluated
histomorphometrically 42 h post infection. Cerebrospinal fluid cytokine levels were analyzed during acute infection.
Five weeks post infection, auditory brainstem responses were measured to determine hearing thresholds.
Spiral ganglion neuron density and abundance of recently proliferated and integrated hippocampal granule
neurons were assessed histologically. Additionally, the anti-inflammatory effect of metformin was studied in
primary rat astroglial cells in vitro.
Results: Upon pneumococcal infection, metformin treatment significantly reduced levels of inflammatory
cytokines and nitric oxide production in cerebrospinal fluid and in astroglial cell cultures in vitro (p < 0.05).
Compared to animals receiving ceftriaxone monotherapy, adjunctive metformin significantly reduced cortical
necrosis (p < 0.02) during acute infection and improved median click-induced hearing thresholds (60 dB vs.
100 dB, p < 0.002) 5 weeks after infection. Adjuvant metformin significantly improved pure tone hearing
thresholds at all assessed frequencies compared to ceftriaxone monotherapy (p < 0.05) and protected from
PM-induced spiral ganglion neuron loss in the inner ear (p < 0.05).
Conclusion: Adjuvant metformin reduces brain injury during pneumococcal meningitis by decreasing the
excessive neuroinflammatory response. Furthermore, it protects spiral ganglion neurons in the inner ear and
improves hearing impairments after experimental pneumococcal meningitis. These results identify adjuvant
metformin as a promising therapeutic option to improve the outcome after pediatric pneumococcal meningitis.
Keywords: Pneumococcal meningitis, Brain injury, Neuroinflammation, Neurologic sequelae, Metformin, Inner ear
damage, Neuroregeneration
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Introduction
Streptococcus pneumoniae and Neisseria meningitidis are
the most prevalent pathogens of childhood meningitis
beyond neonatal age [1, 2]. Pneumococcal meningitis
(PM) is associated with a high risk for neurologic dis-
abilities, as one-third of PM survivors present with
neurofunctional sequelae including hearing loss, epi-
lepsy, cerebral palsy, cognitive impairment, and learn-
ing disability [3–5]. Pneumococci are reported to
reach the brain through the bloodstream after suc-
cessful nasopharyngeal colonization with subsequent
bloodstream invasion and survival [4, 6]. Bacteria are
proposed to transmigrate through the blood-brain
barrier (BBB) by receptor-mediated endothelial adhe-
sion and transcytosis using an interplay between the
platelet-activated factor receptor (PAFr), polymeric Ig
receptor (pIgR), and platelet endothelial adhesion
molecule (PECAM-1) expressed on the host’s endo-
thelial cells [6–11]. Notably, pneumococci might also
gain access to the CNS through a paracellular route
by disrupting the BBB’s integrity via pneumolysin-
and α-glycerophosphate oxidase (GlpO)-induced dam-
age to endothelial cells [12–14]. In addition, pneumo-
coccal CNS infections may arise after local spreading
of bacteria from nearby focal infections (i.e., otitis
media, sinusitis, or mastoiditis). Upon recognition of
the invading pathogens, recruited neutrophils together
with brain-resident immune cells produce high levels
of inflammatory cytokines, reactive oxygen and nitro-
gen species (ROS and RNS), intended to eliminate the
invading pathogens but also causing collateral damage
to the vulnerable brain tissue [4, 15, 16]. This exces-
sive neuroinflammatory response upon pneumococcal
cerebrospinal fluid (CSF) invasion together with
pneumococcal toxins contributes to PM-associated
central and peripheral nervous system (CNS and
PNS) injury [4, 17–20]. A hallmark of PM is the in-
tense neutrophilic pleocytosis in the CSF in reaction
to invading bacteria [21–23]. PM-induced brain injury
is characterized by cortical necrosis—as a conse-
quence of ischemia and hypoxia by a combination of
reduction blood perfusion of the brain with focal
cerebral vasculitis and vasospasms [24, 25]. Apoptosis
in the hippocampal dentate gyrus involving granular
cell progenitors [26–29]—which has been linked to
learning and memory impairment in independent ex-
perimental models [30–32]—represents a second form
of neuronal damage upon PM. Furthermore, spreading
pneumococci and leukocytes from the CSF to the
perilymphatic space of the cochlea result in damage
of cochlear sensory hair cells and spiral ganglion neu-
rons (SGNs) in the inner ear [5, 33–35], being re-
sponsible for hearing loss in up to 30% of surviving
patients [3, 36, 37].
Corticosteroids are recommended as adjuvant therapy
to downmodulate the detrimental inflammation during
PM [38, 39]. In a comprehensive meta-analysis, dexa-
methasone was shown to improve the outcome of adults
with PM and children with meningitis caused by
Haemophilus influenzae type b—without showing a bene-
ficial effect in pediatric PM [38]. In experimental pediatric
PM, dexamethasone even aggravates hippocampal regen-
eration and learning deficiency [32, 40]. Therefore, it is
important to find alternative therapeutic approaches to al-
leviate the diseases burden in children suffering from PM.
Metformin is a biguanide drug widely used for the
treatment of patients with type 2 diabetes since the
1960s. It enhances insulin sensitivity, induces glycolysis,
and suppresses gluconeogenesis in the liver [41]. Metfor-
min activates the adenosine monophosphate-activated
protein kinase (AMPK) in hepatocytes, resulting in the
downregulation of the expression of genes involved in
hepatic gluconeogenesis [42]. Important in the frame-
work of brain inflammation is the finding that AMPK ac-
tivation suppresses the expression of pro-inflammatory
cytokines in lipopolysaccharide (LPS)-injected rats [43]. In
experimental multiple sclerosis, metformin signifi-
cantly reduced neuroinflammation in vitro and in vivo
[44]. Metformin reduced neuroinflammation and hip-
pocampal cell death in diabetic mice, with subsequent
improved performance in spatial memory tests [45]
and was shown to be neuroprotective in experimental
Parkinson’s disease [46]. Furthermore, metformin pro-
tected CA1 pyramidal cell of the hippocampus from
ischemia/reperfusion injury [47] and protected coch-
lear hair cells from gentamicin-induced toxicity [48].
In addition to its neuroprotective effects, metformin
has recently been shown to potently promote neuro-
genesis in the hippocampus and cortex by enhancing
neural precursor self-renewal, proliferation, and differ-
entiation [42, 49]. Increased neurogenesis upon met-
formin treatment resulted in improved memory
formation in multiple experimental models of brain
injury [47, 50–53].
We therefore hypothesize that adjuvant metformin
during acute PM reduces the excessive neuroinflamma-
tion and subsequent brain and cochlear injury—hall-
marks of poor prognosis in PM. In addition, chronic
metformin application may support neuroregeneration,
thereby improving neurofunctional outcomes after PM.
Methods
Infecting organism
A clinical isolate of Streptococcus pneumoniae (serotype
3) from a patient with bacterial meningitis was cultured
overnight in brain heart infusion (BHI) medium, diluted
tenfold in fresh, pre-warmed BHI medium and grown
for 5 h to reach the logarithmic growth phase. The
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bacteria were centrifuged for 10 min at 3100×g at 4 °C,
washed twice, resuspended in saline (NaCl 0.85%), and
further diluted in saline to the desired optical density
(OD570nm). The inoculum concentration was determined
by serial dilution and culturing on Columbia sheep
blood agar (CSBA) plates. Bacterial preparation for S.
pneumoniae D39 wild type (serotype 2) and its non-en-
capsulated mutant R6 were performed as described
above with minor adaptions. Overnight cultivation was
shortened to 8 h and time for logarithmic growth was
reduced to 1.5 h for D39.
In vitro astroglial cells stimulation
Astroglial cells consisting of astrocytes, microglia, and
oligodendrocytes were isolated from infant rat brains at
postnatal day 3 (P3), as previously reported [54]. Briefly,
rats were sacrificed by decapitation and brains were iso-
lated. The cortices were homogenized mechanically in
PBS by pipetting up and down with a 5 ml plastic pip-
ette, centrifuged (500×g, 7 min, 4 °C) and resuspended
in DMEM (Sigma-Aldrich, Merck Switzerland) contain-
ing 5% FCS (Biochrom, Germany), GlutaMAX™ (Ther-
moFisher, Switzerland), and antibiotic-antimycotic
solution (ThermoFisher, Switzerland). After resuspen-
sion, cells were plated in T75 flask (TPP®, Merck) previ-
ously coated with poly-L-ornithine (PLO, 0.01 mg/ml in
PBS, Sigma-Aldrich). On day 11 post isolation, cells were
seeded on PLO-coated 24-well plates, at a density of
200,000 cells/well. Astroglial cells were stimulated with
(a) 10 μg/ml lipopolysaccharide (from Escherichia coli,
L2654, Sigma-Aldrich) in PBS, (b) heat-inactivated S.
pneumoniae serotype 3 (3 × 107 CFU/ml), or (c) living S.
pneumoniae serotype 3 (2 × 107 CFU/ml) treated with
ceftriaxone (CRO, 12 mg/ml, Rocephine, Roche). For
each stimulus, cells treated with metformin (metformin
hydrochloride, 10 mM, Sigma-Aldrich) were compared
to vehicle-treated cells. Heat-inactivation of S. pneumo-
niae serotype 3 was performed in a thermo-shaker
(Thermomixer comfort, Vaudaux-Eppendorf AG,
Switzerland) at 56 °C for 30 min. To confirm serotype-
independent anti-inflammatory properties of metformin,
its effect was further assessed on astroglial cells stimu-
lated with living D39 (6 × 107 CFU/ml) or R6 (7 × 107
CFU/ml) treated with ceftriaxone. The use of ceftriaxone
after stimulation with living bacteria is required to guar-
antee astroglial cell survival. Additionally, it mimics the
in vivo model with antibiotic-induced bacteriolysis,
which initially increases the neuroinflammatory reaction
upon antibiotic treatment initiation.
Quantification of nitric oxide production in vitro
After 24 h of astroglial cell stimulation, 100 μl of the cell
culture supernatant from each well was collected and
centrifuged (13,000 rpm, 5 min, 4 °C), transferred to a
96-well plate, followed by addition of 100 μl Griess re-
agent (Sigma-Aldrich). NO2
− content was determined by
measuring the absorbance at 550 nm with a microplate
reader (Molecular Devices, THERMO max). A serial di-
lution of NaNO2 solution (Sigma-Aldrich) from 100 to
1.5625 μM was measured and used to create a standard
curve for quantification. NO2
− concentration in cell cul-
ture supernatant served as a proxy for NO release, and
is further addressed as NO.
Infant rat model of pneumococcal meningitis
All animal studies were approved by the Animal Care
and Experimentation Committee of the Canton of Bern,
Switzerland (license no. BE 129/14 and 01/18). A well-
established infant rat model of pneumococcal meningitis
was used for this study [35, 55]. Eleven-day-old female
and male Wistar rat pups and their dams were pur-
chased from Charles Rivers (Sulzfeld, Germany). The
dams were provided with tap water and pellet diet ad
libitum. Litters were kept in rooms at a controlled
temperature of 22 ± 2 °C. During the acute phase of the
disease (from infection to 42 h after infection), animals
were housed in a room with natural light. For the long-
term experiments, the animals were transferred to indi-
vidually ventilated cages (IVC) in a room with controlled
12 h light/dark cycles. The pups were infected intracis-
ternally with 10 μl of the inoculum containing 5.22 ±
1.27 × 105 CFU/ml of living S. pneumonia serotype 3.
Control animals were injected with 10 μl saline. Menin-
gitis was confirmed by quantitative analysis of bacterial
titers in the cerebrospinal fluid (CSF) at 18 hpi, where
5 μl of CSF were collected by puncture of the cisterna
magna, followed by serial dilution and cultivation on
CSBA plates.
A total of 174 infant were included in this study,
representing 17 independent experiments with 7, 12, or
14 infant rats per experiment. Seventy-six animals were
investigated during acute PM to assess neuroinflamma-
tion and brain damage, and 98 animals were studied to
investigate neurofunctional outcomes. Infected and
mock-infected animals were randomized for treatment
with adjuvant metformin (50 mg/kg, i.p.) and/or CRO
(100 mg/kg, i.p., twice daily [b.i.d.]). Animals with CRO
monotherapy received a i.p. vehicle injection. All animals
received the same amount of fluids during the experi-
ment. Both therapies were initiated at 18 hpi. For the
acute experiments, clinical scoring was performed by in-
vestigators blinded to treatment modalities of individual
animals. The animals were weighted and clinically
scored according to the following scoring scheme (1 =
coma, 2 = does not turn upright, 3 = turns upright in >
5 s, 4 = turns upright in < 5 s, 5 = normal) at 0, 18, 24,
and before sacrificing at 42 hpi. Spontaneous mortality
was documented. CSF samples at 18, 24, and 42 hpi
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were obtained by puncture of the cisterna magna using a
30-gauge needle. CSF samples were centrifuged (16,
000×g, 10 min, 4 °C) and supernatants were stored at −
80 °C for later CSF cytokine measurements. For long-
term experiments, CRO therapy was continued for the
first 5 days after infection. Animals treated with metfor-
min received chronic daily metformin application for
additional 2 weeks, whereas animals from the CRO
monotherapy group received daily vehicle injections. In
addition, bromodeoxyuridine (BrdU, 50 mg/kg, Sigma-
Aldrich) was given once daily on day 3–5 after infection
combined with CRO. Animals were sacrificed with
pentobarbital (Esconarkon®, 150 mg/kg, i.p., Streuli
Pharma AG, Switzerland) and perfused with 4% parafor-
maldehyde (PFA, Merck) in phosphate-buffered saline
(PBS). Brains and cochleas were harvested and fixed in
4% for histological analysis.
Histomorphometric analysis of cortical damage and
hippocampal apoptosis
Damage to the cerebral structures was quantified in
all animals sacrificed at 42 hpi, as previously de-
scribed by us and other independent research groups
[56–59]. Brains were fixed in 4% PFA and cryopre-
served in 18% sucrose in PBS at 4 °C overnight. Brain
cryosections (45 μm) were systematically sampled
with a cutting frequency of 15 and stained for Nissl
substance with cresyl violet. Cortical damage was de-
fined as areas of decreased neuronal density with
histological features of necrosis, using ImageJ soft-
ware. Dead cells with histological features of apop-
tosis were quantified in 48 visual fields spanning the
hippocampal dentate gyrus by using × 400 magnifica-
tion. Histologic assessment was performed and evalu-
ated by investigators blinded to treatment modalities
of the individual animals.
Analysis of cytokine expression in CSF
Cytokines known to be upregulated during PM (IL-1β,
IL-6, TNF-α, IL-10, and IFN-γ) were assessed using
magnetic multiplex assay (Rat Magnetic Luminex® Assay,
Rat Premixed Multi-Analyte Kit, R&D Systems, Bio-
Techne) on a Bio-Plex 200 station (Bio-Rad Laborator-
ies) as described previously [35, 60]. Five microliter of
CSF harvested at 18, 24, and 42 hpi were diluted to a
final volume of 50 μl. For in vitro samples, 50 μl of cell
culture medium was used undiluted. For each sample, a
minimum of 50 beads was measured. If the concentra-
tion of the sample was below the detection limit, a value
corresponding to the detection limit provided by the
manufacturer was used, considering the dilution factor.
The detection limits for undiluted samples were 2.93 pg/
ml for IL-1β, 23.2 pg/ml for IL-6, 8.95 pg/ml for IL-10,
11.5 pg/ml for TNF-α, and 70.9 pg/ml for IFN-γ.
Assessment of hearing capacity by measuring auditory
brainstem response
Five weeks post infection, auditory brainstem responses
(ABR) were performed to determine the hearing thresh-
olds of the animals, as described previously [35, 60].
Click and pure tone recordings were performed with the
Intelligent Hearing Systems SmartEP system. Animals
were anesthetized with 5% isoflurane (Attane TM, Pira-
mal healthcare). The anesthetized animal was placed on
a heating pad in a soundproof chamber. A rubber facial
mask was put on the animal for continuous delivery of
isoflurane. As soon as the animal was under deep
anesthesia, the isoflurane concentration was reduced to
2%. Subdermal electrodes were placed in the mastoid of
the tested ear (active), at the vertex (reference) and in
the lower limb (ground). Earphones were placed in the
outer auricular canal. Click stimuli and 5-ms pure tone
bursts (4, 8, 16, and 32 kHz) were presented at a rate of
21.1 s−1, ranging from 100 to 20 dB sound pressure level
(SPL) in 10 dB decrements (5 dB decrements close to
threshold). The hearing threshold was defined as the
lowest intensity that induced a visually detectable first
peak. Hearing thresholds were independently analyzed
by investigators blinded to treatment modality.
Immunohistological assessment of spiral ganglion neuron
density
Six weeks post infection, the region of the temporal
bone containing the cochlea was dissected from skull,
fixed in 4% PFA, and then transferred to OsteoSoft®
(Merck) for 7–10 days. OsteoSoft was replaced by 30%
sucrose in PBS 24 h before cutting. Left cochleas were
used for the spiral ganglion histology, whereas the right
ones were kept as back-up. Then, 14 μm sections were
cut and mounted on Superfrost Plus Menzel glass slides.
The staining procedure was performed with a Shandon
Sequenza staining rack (Thermo Fisher Scientific). Sec-
tions were permeabilized for 5 min with 0.1% Triton-X,
followed by blocking with blocking solution (PBS with
2% BSA and 0.01% Triton-X) for 1 h at room
temperature (RT). The primary antibody βIII-tubulin (1:
500, mouse-anti-rat, Promega G712A) was diluted in
blocking solution and incubated overnight at 4 °C. The
sections were rinsed with 3 × 500 μl PBS and incubated
with the secondary antibody (goat-anti-mouse Alexa
Fluor 488, 1:500, Thermo Fisher Scientific, A-11029) for
2 h at RT. After rinsing again, the slides were mounted
with Fluoroshield™ with DAPI (Sigma-Aldrich). Images
of the spiral ganglions were acquired using a fluorescent
microscope (ZEISS Axio, Imager M1, West Germany)
equipped with a digital camera (Zeiss AxioCam HRc).
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Immunohistological assessment of BrdU+ and NeuN+ cells
in the hippocampal dentate gyrus
Brains were harvested 6 weeks post infection and fixed
in 4% PFA for 4 h and stored in PBS at 4 °C for later
embedding in paraffin. Ten micrometer sections were
cut using a microtome (Microm, Germany). Every 18th
section was sampled on Superfrost Plus Menzel glass
slides and air dried. Sections were deparaffinized and
submitted to antigen retrieval by incubating the slides in
sodium citrate (Merck KGaA) 10 mM pH 6.0 for 1 h in
a 95 °C water bath. The brain sections were perme-
abilized and blocked as described above. The primary
antibodies BrdU (1:500, sheep-anti-rat, abcam, ab1893)
and NeuN (1:500, mouse-anti-rat, Millipore, MAB377)
were diluted in blocking solution, added to the slides
and incubated overnight at 4 °C. The slides were washed
3 × 5 min with PBS and the secondary antibodies—don-
key-anti-sheep Alexa Fluor 488 (1:500, Thermo Fisher
Scientific, A11015) and donkey-anti-mouse Cy3 (1:500,
Jackson ImmunoResearch, 715-165-151)—were added
for 2 h at RT. After washing the sections 3 × 5 min in
PBS, they were mounted with Fluoroshield containing
DAPI and kept at 4 °C in dark until imaging. BrdU+ cells
in the NeuN+ region of the dentate gyrus were quanti-
fied using a × 400 magnification on fluorescent micro-
scope. The first six sampled sections containing the
dentate gyrus with the upper and lower blades con-
nected were quantified. A mosaic picture of each dentate
gyrus was created with Zeiss AxioVision software using
individual pictures taken with the DAPI fluorescence
channel at × 100 magnification. The mosaic was used for
determining the area of the dentate gyrus with ImageJ
software. Number of BrdU+ cells were then calculated
and evaluated as number of BrdU+ cells per mm2 den-
tate gyrus granule cell layer.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism (Prism 7; GraphPad Software Inc., San Diego,
USA). Results are presented as mean values ± standard
deviation if not stated otherwise. Survival was calculated
using a log rank (Mantel-Cox) test. To compare differ-
ences between means of two normally distributed
groups, an unpaired Student t test or Welch’s t test were
used (cortical damage assessed with Welch’s t test). To
assess differences between non-normal distributed data
(hearing thresholds, hippocampal apoptosis), a non-
parametric Mann-Whitney test was used. A two-way
ANOVA was performed to analyze differences between
treatment modalities and to pure-tone hearing frequen-
cies. Repeated-measure ANOVA was used to assess dif-
ferences in spiral ganglion neuron density from the
three cochlear regions (base, middle, apex). Repeated-
measure ANOVAs were executed on STATA 12 (STATA
Corp., College Station, TX). A p value of < 0.05 was con-
sidered statistically significant with p < 0.05 (*), p < 0.01
(**), p < 0.001 (***), and p < 0.0001 (****).
Results
Adjuvant metformin reduces inflammatory cytokine levels
and nitric oxide production in vitro
Primary astroglial cell cultures from infant rats were
stimulated with LPS, heat-inactivated (HI P21), or liv-
ing S. pneumoniae serotype 3 (living P21) and treated
with metformin. All three stimuli potently activated
astroglial cells in vitro as determined by increased
levels of inflammatory cytokines and NO in the cell
culture medium (Fig. 1a–f ). In LPS-stimulated cells,
metformin significantly reduced the release of IL-1β
(p = 0.0109), IL-6 (p = 0.0050), and NO (p = 0.0024)
and showed trends toward reduced levels of IL-10
(p = 0.069) and TNF-α (p = 0.056). Metformin also
drastically reduced the release of IL-1β (p = 0.0004),
IL-6 (p = 0.0003), IL-10 (p = 0.0015), TNF-α (p <
0.0001), and NO (p = 0.0003) induced by HI P21
stimulation. After exposure to living bacteria, adjuvant
metformin to ceftriaxone treatment attenuated the
levels of IL-6 (p = 0.0229) and NO (p = 0.0005), with-
out significantly affecting the other measured cyto-
kines. Of note, levels of IL-1β and TNF-α were
considerably higher in astroglial cells exposed to liv-
ing bacteria compared to HI P21 and LPS. Addition-
ally, in contrast to the clear release of IL-10 in HI
P21 and living P21 stimulated cells, LPS only margin-
ally induced IL-10 production (Fig. 1c). In non-stimu-
lated control cells, the production of cytokines and
NO was at very low levels (IL-1β < 10 pg/ml; IL-6 <
105 pg/ml; IL-10 < 35 pg/ml; TNF-α < 65 pg/ml; IFN-
γ < 85 pg/ml; NO < 0.5 μM, data not shown). The
anti-inflammatory effect of metformin was further
confirmed to be independent of serotype-specific sur-
face polysaccharides, as metformin treatment also sig-
nificantly reduced the release of IL-1β, IL-6, TNF-α,
and NO after stimulation of astroglial cells with S.
pneumoniae serotype 2 (D39, see Additional file 1).
These anti-inflammatory properties were further doc-
umented to be capsule-independent as metformin sig-
nificantly reduced the release of IL-1β, IL-6, TNF-α,
and NO to a similar extent after astroglial cell stimu-
lation with R6—a non-encapsulated mutant of D39
(see Additional file 1).
Adjuvant metformin does not affect clinical parameters
during acute PM
Overall, 174 infant Wistar rats were included in the
study. All animals infected with S. pneumoniae serotype
3 (n = 140) developed meningitis, which was proven by
growth of bacteria (≥ 106 CFU/ml) in CSF samples
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obtained at 18 hpi and the appearance of meningitis
symptoms reflected by clinical score < 5, weight loss,
and changes in posture. Sixty-one infected infant rats
were treated with adjuvant metformin (50 mg/kg) in
addition to CRO, and 79 infected rats received CRO
monotherapy. The slightly lower number of animals re-
ceiving metformin is explained by an initially performed
dose-finding study evaluating different metformin con-
centrations, whereupon all animals receiving a metfor-
min dose different from 50 mg/kg were excluded from
subsequent analysis.
Survival was significantly reduced in infected animals
(PM+) compared to mock-infected animals (PM−). Ad-
juvant metformin treatment did not affect survival in
neither infected nor non-infected animals compared to
animals treated with CRO monotherapy (Fig. 2a).
Relative weight change showed a significant difference
between infected and mock-infected animals during
acute infection. In both infection groups, however, rela-
tive weight change was not altered by adjuvant metfor-
min treatment neither during acute phase nor by
chronic application (Fig. 2b, c).
Adjuvant metformin therapy reduces levels of
inflammatory cytokine in CSF and cortical necrosis but
not hippocampal apoptosis
Inflammatory cytokines were measured before treatment
initiation and at 6 h and 24 h after therapy start, repre-
senting 18, 24, and 42 hpi. Immediately before treatment
initiation with CRO ±metformin at 18 hpi, infected
animals from both groups—adjunctive metformin and
CRO monotherapy—showed comparable levels of CSF
A B C
D E F
Fig. 1 Reduced levels of inflammatory cytokines and NO after stimulation of astroglial cells in vitro. Primary neonatal rat astroglial cells were
either stimulated with LPS, heat-inactivated (HI P21), or living S. pneumoniae serotype 3 (Living P21) in the presence or absence of metformin.
Metformin significantly reduced levels of IL-1β (p = 0.0109 in LPS- and p = 0.0004 in HI P21 stimulated cells, a). IL-6 (p = 0.0050 in LPS-, p = 0.0003
in HI P21- and p = 0.0229 in living P21-stimulated cells, b) and nitric oxide (p = 0.0024 in LPS-, p = 0.0003 in HIP21- and p=0.0005 in living P21-
stimualted cells, f) levels were significantly reduced by metformin independent of stimulating agents. IL-10 (p = 0.0015, c) and TNF-α (p < 0.0001,
d) levels were significantly reduced in astroglial cells stimulated by HI P21 in the presence of metformin. No effect of metformin treatment on
IFN-γ levels (e) was found
A B C
Fig. 2 Survival and weight change in infant rats with pneumococcal meningitis. Infected rats showed significantly reduced survival compared to
mock-infected animals, independent of treatment regimen (a). Weight change during acute meningitis (b) and long-term recovery (c) was
significantly affected by infection but not by adjuvant metformin therapy
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cytokines and bacterial CSF titers, representing a com-
parable degree of infection and neuroinflammation at
time of treatment initiation (Fig. 3a–e). Six hours after
treatment initiation, adjuvant metformin therapy signifi-
cantly reduced CSF levels of the inflammatory cytokines
IL-1β (p = 0.015 and p = 0.034 at 24 h after treatment
initiation), IL-6 (p = 0.036), and TNF-α (p = 0.044). No
significant difference was found for IFN-γ and IL-10, al-
though IL-10 showed a trend toward reduction (p =
0.059, Fig. 3c).
No cortical damage was found in mock-infected ani-
mals. Infected animals treated with adjuvant metformin
had significantly reduced cortical necrosis compared to
infected animals receiving CRO monotherapy (mean of
damaged cortex volume 0.76% ± 0.47, n = 16, vs. 3.34% ±
0.83 in CRO monotherapy, n = 32, p = 0.0101, Fig. 3f ).
Apoptotic cells were found in the subgranular zone of
the hippocampal dentate gyrus. Hippocampal apoptosis
was found at physiological levels in mock-infected ani-
mals. Adjuvant metformin treatment did not signifi-
cantly affect hippocampal apoptosis in infected animals
(see Additional file 2).
Metformin treatment reduces PM-induced hearing loss
and protects spiral ganglion neurons
Five weeks after infection, hearing thresholds were
determined by recording response to click stimula-
tions and pure tones on both ears. In infected ani-
mals, metformin treatment significantly improved
click-induced hearing thresholds compared to ani-
mals with CRO monotherapy (60 dB, n = 44, in met-
formin therapy vs. 100 dB, n = 36 in CRO
monotherapy, p = 0.0015, Fig. 4a). Pure tone ABR
showed higher thresholds for all assessed frequencies
(4, 8, 16, and 32 kHz) in infected animals compared
to mock-infected animals (n = 44, p ≤ 0.0001, two-way
ANOVA, Fig. 4b). Infected animals receiving adju-
vant metformin treatment showed significantly better
pure tone hearing capacity than animals treated with
ceftriaxone monotherapy (p = 0.0013, Fig. 4b). Fre-
quency-specific analysis revealed that at all measured
frequencies, hearing capacity was significantly im-
proved in infected animals receiving adjuvant met-
formin compared to CRO monotherapy (4 kHz p =
0.0023, 8 kHz p = 0.0026, 16 kHz p = 0.0029, 32 kHz
p = 0.0248, Fig. 4b).
The densities of spiral ganglion neurons (SGNs) were
assessed by counting SGNs in the basal, middle, and ap-
ical turns of mid-modiolar cochlea sections. A signifi-
cant reduction of SGNs in the basal turn was
determined in infected animals treated with CRO mono-
therapy compared to mock-infected animals (1945 ±
141.7, SGNs/mm2 in CRO monotherapy animals, n = 11
vs. 2299 ± 63.6 SGNs/mm2 in mock-infected animals,
n = 15, p = 0.0197). This PM-induced neurotoxicity of
SGNs was prevented by adjuvant metformin treatment
with no detectable SGN loss in these animals (2211 ±
107.1 SGNs/mm2 in animals receiving metformin, n =
A B C
D E F
Fig. 3 Inflammatory CSF cytokine levels, bacterial titers and cerebral complications during acute pneumococcal meningitis. Six hours after
treatment initiation, adjuvant metformin significantly reduced levels of IL-1β (p = 0.015 and p = 0.034 at 24 h after treatment initiation, a), IL-6 (p =
0.036, b), and TNF-α (p = 0.044, d) and showed a trend toward reduced IL-10 levels (p = 0.059, c), despite having comparable CSF cytokine levels
and bacterial titers at time of therapy initiation (a–e). Adjuvant metformin significantly reduced levels of cortical necrosis at 42 h post infection
(p = 0.0101, f)
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14, p = 0.475, Fig. 4c). A repeated-measure ANOVA,
which considered the different cochlear turns as re-
peated measurements, revealed a significant protective
effect of adjuvant metformin on SGN density over all
cochlear turns in infected rats compared to CRO mono-
therapy (p = 0.0219).
Metformin does not promote neurogenesis in the
hippocampal neural stem cell niche
Neurogenesis was defined by cells being BrdU+ and
NeuN+, i.e., cells which have proliferated and incorpo-
rated BrdU after acute infection and successfully
matured to neurons and integrated into existing hippo-
campal network 5 weeks after infection. BrdU+ cells
were mostly found in the subgranular zone and the
granule cell layer of the dentate gyrus (DG) (Fig. 5a, b),
indicating their integration into hippocampal network.
BrdU+ cells in the NeuN+ region of the DG were quanti-
fied to assess neuronal proliferation and survival. The
results revealed no significant difference between mock-
infected and infected animals as well as animals which
were chronically treated with metformin or their litter-
mates which received chronic vehicle injection (Fig. 5c).
Discussion
In the present study, we investigated the anti-inflammatory,
neuroprotective, and neuroregenerative effects of adjuvant
metformin in PM. Our results demonstrate that treatment
with adjuvant metformin in pediatric experimental PM de-
creases neuroinflammation, as reflected by reduced levels
of inflammatory cytokines in the CSF, resulting in an atten-
uated cortical necrosis. These anti-inflammatory properties
of metformin were further supported by results from
additional in vitro experiments. Furthermore, metformin
protected SGNs from PM-induced cell death and reduced
PM-induced hearing loss.
Damage to the brain caused by PM is multifactorial, but
mainly associated with an excessive inflammation, result-
ing in long-lasting neurological sequelae [5, 29, 33]. Rapid
growth of S. pneumoniae in the subarachnoid space and
released bacterial products induce a severe inflammatory
response. This response may even be exacerbated after
treatment with bacteriolytic antibiotics [4]. Based on these
observations, adjunctive therapies are needed to attenuate
the hyperinflammation in the brain during PM.
Dexamethasone—an anti-inflammatory corticosteroid—is
currently recommended as adjuvant therapy for adults
and children with PM [38]. We have previously shown in
the present model that therapy with dexamethasone
showed only limited protection from PM-induced hearing
loss and aggravated mortality, weight loss, and hippocam-
pal injury with associated learning deficiency when com-
pared to CRO monotherapy [32, 40, 61]. In the present
study, we specifically compared metformin therapy to
CRO monotherapy but not to adjuvant dexamethasone
therapy.
In vitro, primary neonatal rat astroglial cells were
stimulated with LPS, heat-inactivated and living S.
pneumoniae in the presence or absence of metformin.
The anti-inflammatory effect of metformin in LPS-
stimulated macrophages and microglia has already
A
B
C
Fig. 4 Hearing capacity and spiral ganglion neuron (SGN) density
assessed 5 weeks after infection. Metformin therapy significantly
improved click (p = 0.0015, a) and pure tone (4 kHz p = 0.0023, 8 kHz
p = 0.0026, 16 kHz p = 0.0029, 32 kHz p = 0.0248, b) hearing
thresholds in infected animals, without having an effect on hearing
capacity in healthy animals (a). SGNs from the basal turn were
protected from PM-induced cell death by metformin therapy
(p = 0.0219, c)
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been shown in vitro, where metformin significantly
reduced the release of inflammatory cytokines and
NO in an AMPK-dependent manner [44, 50]. The
present in vitro results confirm the anti-inflammatory ef-
fects of metformin in LPS-induced neuroinflammation in
primary astroglial cells. Furthermore, metformin reduced
cytokines and NO levels caused by stimuli relevant for
PM-induced neuroinflammation, like heat-inactivated or
living pneumococci (Fig. 1a–f ). We only found statistical
trends for reduced IL-1β and TNF-α levels after stimula-
tion with living P21 and treatment with metformin in
vitro. However, the anti-inflammatory effect of metformin
was further confirmed when stimulating the cells with liv-
ing D39 and R6 with significant reduction for IL-1β, IL-6,
TNF-α, and NO. Significant reduction of IL-1 β, IL-6, and
TNF-α were also observed in the CSF of infected animals
treated with metformin. As cytokines are important medi-
ators of cerebral damage during PM, any reduction in in-
flammatory mediators might mediate neuroprotection in
vivo [4]. The induction of most inflammatory mediators
was comparable between the different stimuli, but we
found notable differences such as poorly induced IL-10
levels after stimulation with LPS (Fig. 1c) or significantly
higher IL-1β and TNF-α responses of cells exposed to liv-
ing pneumococci (Fig. 1a, d). Lower levels of IL-1β and
TNF-α in heat-inactivated pneumococci might be ex-
plained by the heat-lability of the highly immunogenic
pneumolysin [13, 62]. Notably, the anti-inflammatory ef-
fect of metformin in vitro was confirmed after stimulation
with a non-vaccine pneumococcal serotype (serotype 2,
D39) and its non-encapsulated mutant R6, demonstrating
that metformin’s anti-inflammatory properties are
serotype- and capsule-independent and also potently re-
duces inflammatory mediators after infection with a non-
vaccine serotype (Additional file 1). Low and unaffected
levels of IFN-γ can be explained by the absence of T lym-
phocytes and NK cells in our cell culture, the two cell
types mainly responsible to induce IFN-γ responses [63].
Additionally, IFN-γ serves mostly to combat intracellular
pathogens [63], and only to a lesser extend against extra-
cellular bacteria like S. pneumoniae. Comparison between
the different stimuli should be interpreted with caution,
since the kinetics of cytokine release may be different for
each stimulus and we determined the accumulation of cy-
tokines in the supernatant 24 h after stimulation.
In the in vivo study, the dose of metformin (50 mg/kg)
was chosen based on preliminary pilot study and other in-
dependent studies [43, 51]. The use of a higher metformin
dose (200 mg/kg) in our pilot study resulted in signifi-
cantly increased mortality and hippocampal apoptosis in
infected animals treated with adjuvant metformin com-
pared to infected animals treated with CRO monotherapy
(see Additional file 2). On the other hand, 20 mg/kg met-
formin did not protect from PM-induced cortical damage
(data not shown). Although adjuvant metformin has been
reported to cause weight loss in type 2 diabetes patients
[64], we did not detect significant differences in weight
change between animals receiving adjuvant metformin
and animals with CRO monotherapy during acute (Fig. 2b)
and post-acute (Fig. 2c) phases of PM—independent of in-
fection with S. pneumoniae. In addition, metformin treat-
ment did not affect survival (Fig. 2a). Together, these data
indicate that 50 mg/kg metformin during acute PM and
during recovery from PM is safe as it does not affect
A B
C
Fig. 5 Quantification of BrdU+ cells in the NeuN+ region of the hippocampal dentate gyrus. BrdU-positive neurons (green) are clearly visible in
the granular zone of the dentate gyrus (a, b). Adjuvant metformin treatment did not promote neurogenesis neither after experimental PM nor in
mock-infected animals, as no significant differences in BrdU+ cell counts was detected between animals receiving metformin treatment and
animals receiving CRO monotherapy (c)
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mortality or weight loss. Although we found promising re-
sults using 50 mg/kg metformin as adjuvant therapy in
PM, further studies are needed to identify the influence of
dosing on these reported effects.
Inflammatory cytokines produced by infiltrating leuko-
cytes and brain-resident cells are crucially involved in
the pathogenesis of PM [4]. During the acute phase of
PM, levels of pro-inflammatory cytokines are drastically
increased [4, 22, 55]. Metformin-dependent AMPK acti-
vation was shown to induce anti-inflammatory effects
[43]. In this study, we found that adjuvant metformin
significantly reduced CSF levels of inflammatory cyto-
kines in vivo (Fig. 3) and in vitro (Fig. 1). In vivo, treat-
ment with CRO monotherapy caused a transient
increase of IL-1β and IL-6. This may be due to the anti-
biotic-induced lysis of bacteria caused by CRO—indu-
cing a brisk release of highly immunogenic bacterial
products [65]—leading to an elevated acute inflamma-
tion [4, 66, 67]. In contrast, levels of IL-1β and IL-6 de-
creased in animals treated with adjuvant metformin,
indicating its anti-inflammatory effect. The kinetic of
TNF-α release was different, with a steady decrease in
infected animals, independent of the treatment. How-
ever, the decrease was more pronounced in animals
treated with adjuvant metformin 6 h after therapy. No
significant reduction of IFN-γ by adjuvant metformin
could be detected in vivo and in vitro. For IL-10, only a
trend toward reduction when treated with adjuvant met-
formin was found in vivo (p = 0.0591, Fig. 3c). Our
findings of reduced neuroinflammatory parameters in
vitro and in vivo are in line with previously reported
studies, where metformin was able to reduce neuroin-
flammation in different experimental neuroinflammatory
diseases [43–45, 50].
The pathogenesis of cortical brain injury is complex
and involves vasculitis in cerebral blood vessels
caused by inflammation of the surrounding subarach-
noid space [24, 25, 55, 68]. With adjuvant metformin
therapy, a significant reduction in cortical necrosis
was detected (Fig. 3f ). We hypothesize that an overall
reduction of inflammatory parameters (cytokines and
NO) by adjuvant metformin within the first hours
after treatment initiation led to an attenuation of cor-
tical damage—a correlation previously found with
other anti-inflammatory adjuvant therapies in this in-
fant rat PM model [58, 60, 69]. Comparable CSF
cytokine levels 24 h after treatment start between
metformin-treated and untreated animals are ex-
plained by the fast decline of CSF cytokines after
treatment initiation, leading to low or even undetect-
able levels at this time point. This is in line with pre-
viously reported clinical and experimental data [21,
58, 60, 69, 70]. Nevertheless, hippocampal apoptosis
was not affected with this dose of adjuvant metformin
(see Additional file 2). Notably, prevention of hippo-
campal apoptosis in experimental infant rat PM has
so far only been repetitively described with caspase-3
inhibitors, inhibitors of matrix-metalloproteinase, and
TNF-α converting enzyme (TACE) or modulators of
neurogenesis [55, 58, 71–73].
During the acute phase of PM, infiltration of pneumo-
cocci and leukocytes from the CSF into the basal turn of
the cochlea via the cochlear aqueduct causes damage to
the sensory hair cells and spiral ganglion neurons, result-
ing in sensorineural hearing loss [3, 33, 35–37, 74]. Pre-
vious studies demonstrated the ototoxic effect of TNF-α
in vivo and in vitro [75, 76], and reported a positive cor-
relation of CSF TNF-α levels with increased hearing loss
after PM [35]. Additionally, reactive oxygen species and
NO are known mediators of blood-labyrinth barrier dis-
ruption and sensorineural hearing loss after bacterial
meningitis [77–79]. A reduction of inflammatory cyto-
kines during acute experimental PM was shown to im-
prove subsequent hearing capacity [60, 69, 80]. In the
present study, adjuvant metformin therapy significantly
improved hearing capacity 5 weeks after infection
(Fig. 4a–c). In infected animals, metformin treatment
significantly improved median click hearing thresholds
compared to animals with CRO monotherapy by 40 dB
(60 dB vs. 100 dB in CRO monotherapy, p = 0.0015,
Fig. 4a). Frequency-dependent analysis showed that
hearing was significantly improved by adjuvant metfor-
min treatment in all assessed frequencies (4, 8, 16, and
32 kHz, Fig. 4b). In previous work, Perny et al. demon-
strated that SGNs were affected depending on the sever-
ity of infection. The highest degree of SGN loss
occurred in a basal to apical gradient, with a more pro-
nounced hearing loss for the higher frequencies [35]. In
accordance with these data, quantification of SGNs pre-
sented a significant reduction of SGNs in the basal turn
of infected animals treated with CRO monotherapy, an
effect that was prevented by adjuvant metformin therapy
(Fig. 4d). Protection of SGNs during acute PM is crucial
to maintain hearing capacity [35]. Previous studies using
otoprotective compounds that attenuated the loss of
SGNs were able to decrease PM-induced sensorineural
hearing loss [60, 80]. Repeated-measure ANOVA showed
a significant protective effect of adjuvant metformin in in-
fected animals over all three cochlear turns, explaining the
improved hearing threshold in all assessed frequencies.
Thus, we suggest that metformin also reduced the levels
of ototoxic inflammatory mediators in the cochlea and
protected the SGNs from PM-induced toxicity. However,
a significant protection of SGNs was only demonstrated in
the basal turn, representing high-frequency hearing.
Therefore, there must be additional explanations for the
improvement of hearing capacity at middle and low fre-
quencies. Since metformin is known to protect auditory
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hair cells in an ototoxicity model mediated by gentamicin
[48], a preservation of cochlear hair cells during PM might
explain our reported improvement of pure tone hearing
capacity at all measured frequencies. The protection of
presynaptic ribbons of surviving hair cells would be an-
other possible explanation for improved hearing without
detectable changes in SGNs [35].
Neurogenesis describes the generation, maturation, and
integration of newborn neurons into the pre-existing neur-
onal network [81]. It has recently been shown that metfor-
min promotes neurogenesis and neuronal differentiation in
the hippocampus and thereby improves spatial memory
formation in rodents [42, 49, 82]. In this study, adjuvant
metformin did not significantly increase the number of sur-
viving BrdU+ cells in the NeuN+ region of the DG—neither
in infected nor in mock-infected animals. A possible ex-
planation might be the developmental stage of the hippo-
campus. Most studies showing significantly increased
neurogenesis upon metformin treatment were performed
in adult or adolescent models [49, 50, 52, 53, 82]. These re-
sults might therefore differ from our infant model, in which
the level of endogenous neurogenesis is already consider-
ably high. In addition, studies that showed a significant in-
crease in neurogenesis with increased numbers of BrdU+
cells in the hippocampal DG used a higher dose of metfor-
min (200 mg/kg) [49, 82]. In our study, we had to reduce
the dose to 50 mg/kg, as 200 mg/kg metformin increased
mortality during acute PM (see Additional file 2). This re-
duced dose might have limited the neuroregenerative cap-
acity of metformin. Many studies reported increased
neurogenesis after different CNS damage like traumatic
brain injury [83], stroke [84], Alzheimer’s disease [85], or
neonatal inflammatory pain [86]. We have previously
shown in the present model that the rate of cell division in
the dentate gyrus increased significantly in the first days
after infection [87]. However, no statistical difference be-
tween infected and mock-infected animals was found when
the survival of this pool of cells born shortly after infection
was tested 5 weeks later. Nevertheless, this is in line with
similar findings in a mouse model of PM showing a transi-
ent increase of neurogenesis after PM, which is not detect-
able anymore at 5 weeks after infection [88]—representing
the time when we sacrificed our animals.
Generally, manipulation of the hippocampal neurogenic
niche with the intention to induce and activate endogen-
ous neuroregeneration after pneumococcal meningitis-in-
duced cell death aims for compensating damage that
occurred during acute infection and represents another
alternative therapeutic approach to improve the outcome
after pediatric pneumococcal meningitis. Therapies pro-
moting endogenous neuronal repair by activating neural
stem cells would allow a therapeutic window that could
be initiated later and for longer time when compared to
adjunctive anti-inflammatory substances given during
acute pneumococcal meningitis. It was therefore recently
argued that future research should focus increasingly on
neuroregeneration [89]. However, different neurogenic
substances—experimentally shown to induce neurogenesis
and improve learning and memory in non-infectious
models [49, 72, 82]—failed to increase neurogenesis after
pneumococcal meningitis [72]. Furthermore, for other
neurogenic substances like neurotrophin-3 and BDNF, it
has not been investigated so far whether the improved
outcomes derive from neuroprotection during acute
infection or increased neuroproliferation during chronic
application [71, 90–92]. Nevertheless, the combination of
anti-inflammatory and neuroprotective metformin with a
potent inducer of neuroregeneration (BDNF or DHF [93])
may potentially improve the chance for successful neuror-
egeneration after PM-induced hippocampal damage.
Conclusion
Treatment with metformin is neuro- and otoprotective
in experimental pediatric PM. Metformin exerts its neu-
roprotective effects by reducing neuroinflammation,
demonstrated by decreased CSF levels of inflammatory
cytokines and reduced NO production in vitro and in
vivo with subsequently reduced cortical damage. In
addition, adjuvant metformin improves hearing capacity
compared to standard ceftriaxone monotherapy and pro-
tected spiral ganglion neurons from PM-induced cell
death. Although we could not confirm metformin’s neu-
roregenerative properties in this study, the results iden-
tify metformin as a highly promising therapeutic option
to improve the outcome of PM and other neuroinflam-
matory diseases.
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Additional file 1: Inflammatory mediators after S. pneumoniae serotype
2 infection in vitro. Primary neonatal rat astroglial cells were either
stimulated with living S. pneumoniae serotype 2 (D39) or its non-
encapsulated mutant R6 in presence or absence of metformin. Metformin
significantly reduced levels of IL-1β (A, both p < 0.0001), IL-6 (B, p <
0.0001 for D39 and p = 0.0006 for R6), TNF-α (D, p < 0.0001 for D39 and
p = 0.0002 for R6) and nitric oxide (E, both p < 0.0001). Levels of IL-10
were not affected by treatment with metformin (C). (PDF 376 kb)
Additional file 2: Survival, cortical necrosis and hippocamapal
apoptosis in dose-fining study. Mortality was significantly increased by
adjunctive 200 mg/kg metformin compared to CRO monotherapy and
showed a trend to be higher than adjunctive 50 mg/kg metformin (A).
Adjunctive 200 mg/kg metformin significantly reduced cortical necrosis at
42 hpi (B), while showing significantly increased hippocampal apoptosis
(C) compared to CRO monotherapy. (PDF 385 kb)
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